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Abstract
Background: Transcatheter treatment has become the method of choice for treating many
heart defects. Recently, Cardio-O-Fix occluder (COF) — a new, self-expandable nitinol wire-
-mesh device very similar to the Amplatzer device — has been introduced into clinical practice.
To the best of our knowledge, this is the first publication related to its application.
Methods: Five patients aged from six months to 69 years were included in the study: two with
atrial septal defect (ASD), one with patent foramen ovale (PFO) after cryptogenic stroke, and
two with patent ductus arteriosus (PDA). These latter two comprised one six month old infant
with co-existent hypertrophied cardiomyopathy, and a 53 year-old woman with recanalized
PDA after previous ligation. All were treated percutaneously with COF. There was no prelimi-
nary patient selection. The only limitation was the size of the devices in our possession (16 and
22 mm ASD COF, 25 PFO COF, 4/6 and 6/8 PDA COF). The implantation technique was
the same as previously described for Amplatzer occluders.
Results: All procedures were finished successfully with complete closure of the shunt. No
complications were observed during a six month follow-up. In the child with PDA, we observed
decrease of gradient from 80 to 60 mm Hg in hypertrophied left ventricular outflow tract,
although a  small protrusion of PDA-COF device was noted in the descending aorta (8 mm Hg
gradient in ECHO). In the patient with recanalized PDA, the procedure was performed after
arterio-venous loop creation. Mean fluoroscopy time was 4.4 (range from 1.6 to 11) minutes.
Conclusions: Our preliminary experience indicates that the application of Cardio-O-Fix
devices is safe and effective. (Cardiol J 2010; 17, 6: 607–611)
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Introduction
Transcatheter closure of atrial septal defects
(ASD), patent foramen ovale (PFO) and patent duc-
tus arteriosus (PDA) has in recent years become the
treatment of choice. For these purposes, the common-
est equipment used have been expensive Amplatzer
devices. Recently, Figulla occluders, similar to Am-
platzers, have been introduced to clinical practice [1].
This study sets out our preliminary experience
in using new devices from the family of Cardio-O-
-Fix occluders (COF), which are also similar to Am-
platzer devices. All are made from nitinol wire mesh.
COF occluders received CE approval (CE 0197) in
2008. To the best of our knowledge, this paper is the
first publication reporting the use of these devices
for transcatheter ASD, PFO and PDA closure.
Methods
In September 2009, five consecutive patients
were treated with COF: two with ASD, two with
PDA and one with PFO. There was no preliminary
patient selection — the only limitation was the size
of the devices we possessed. ASD, PDA and PFO
COF occluders (Starway Medical Technology Inc.
Beijing, China) show many similarities in their
structure, size, diameter, implantation technique
and application to Amplatzer devices. The ASD COF
occluder is a self-expandable double disc device
(Fig. 1). Before implantation, the stretched diame-
ter of the defect was measured using a calibrating
balloon. The PDA COF occluder is a self-expanda-
ble, mushroom-shaped device (Fig. 2). After aor-
tography in lateral projection, the anatomy of the
PDA was assessed. According to the measured size
of PDA, a device between 2–4 mm larger than its
narrowest diameter was chosen for closure. The
PFO COF occluder is a self-expandable double disc
implant device (Fig. 3). In the 25 mm PFO COF oc-
cluder, the right disc diameter is 25 mm and the left
is 18 mm. No measurement of the stretched diam-
eter of PFO was made before transcatheter closure.
In the case of ASD and PFO COF applications after
procedures, heparin infusions were administered
for two days. Thereafter, aspirin (3–
–5 mg/kg) was prescribed for six months.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Patients 1 and 2
These were a 24 year-old man (weight 84 kg)
and a 69 year-old woman (weight 60 kg) with ASD.
Figure 1. Atrial septal defect Cardio-O-Fix occluder. Figure 2. Patent ductus arteriosus Cardio-O-Fix occluder.
Figure 3. Patent foramen ovale Cardio-O-Fix occluder.
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In transthoracic echocardiography (TTE), right
atrium and right ventricle overload was observed.
The diameter of the defect was estimated as
15 mm in the first patient and 10 mm in the second.
In transesophageal echocardiography (TEE), ASD
diameters were 17 mm and 12 mm respectively.
Procedures were performed under local anesthe-
sia with TEE and fluoroscopic guidance. Stretch
diameters of ASD were 20 mm and 16 mm respec-
tively. Through a 12 F delivery sheath, the 22 mm
ASD COF was implanted in the first patient, and
through a 9 F sheath the 16 mm ASD COF in the
second (Fig. 4). Procedural times were 30 and
40 min, and fluoroscopy times 2.3 and 2 min respec-
tively. Complete closure of ASD was confirmed
in TTE the day after the procedure in both pa-
tients.
Patient 3
This was a 32 year-old woman (weight 62 kg)
with PFO and a history of previous cryptogenic
stroke (six months earlier). In cerebral TC, ische-
mic stroke was confirmed. TEE (with contrast right
atrium study) and transcranial Doppler (TCD) study
in the middle cerebral artery (with saline injected
into the peripheral vein) demonstrated positive
signs of significant right to left shunt during Val-
salva maneuver. Procedure was performed under
local anesthesia and both TEE and fluoroscopic con-
trol. Through an 8 F delivery sheath, the 25 mm
PFO COF occluder was implanted. Procedural time
was 45 min, fluoroscopy time 1.6 min.  The next day,
control TCD revealed no shunt and bubbles in the
medial cerebral artery (before the procedure ‘show-
er’ was present).
Patient 4
This was 53 year-old woman (weight 66 kg)
with PDA previously ligated surgically (in 1976).
Recanalization of PDA was stated few years ago.
In diagnostic catheterization, the  pressure in the
aorta was 173/76/116 mm Hg and in the pulmonary
artery 37/14/26 mm Hg. Due to the difficulty of pre-
cisely measuring the PDA diameter during conven-
tional aortography (wide aorta and duct), it was es-
timated as 3.5 mm using a calibrating balloon [2].
Another technical problem was catheterization of
PDA from the venous side. An arterio-venous loop
was created with a guidewire 0.035 × 260 cm [3].
From the venous side through a 7 F delivery sheath
(with angulation of 180 degrees), a 8/6 mm PDA
COF was implanted. After release of the device, aor-
tography proved its proper position and complete
closure of PDA. Procedural time was 50 min, fluo-
roscopy time 11 min.
Patient 5
This was a six and a half month old boy (weight
8.9 kg) with PDA and diagnosis of hypertrophied
cardiomyopathy (with obstruction of left ventricu-
lar outflow tract (LVOT) with 80 mm Hg gradient
in Doppler echocardiography. The procedure was
performed under general anesthesia with fluoro-
scopic control. After diagnostic catheterization,
(pressure in left ventricle 150/0/5 mm Hg, in aorta
75/42/56 mm Hg, in pulmonary artery 35/15/21 mm
Hg), the diameter of PDA (in aortography) was es-
timated as 2.5 mm Hg. Through a 6 F delivery
sheath (with angulation of 180 degrees), a 6/4 mm
PDA COF was implanted. The only difficulty which
occurred during the procedure was kinking of the
Figure 4. Echocardiographic images of atrial septal defect: A. Before and; B. After transcatheter closure with Cardio-
-O-Fix occluder atrial septal defect occluder.
A B
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trans-septal sheath in the aorta close to PDA dur-
ing the introduction of the device. This problem was
resolved by repositioning the long sheath in the
descending aorta. As a consequence, kinking of the
sheath disappeared, possibly because it was stabi-
lized by a stiff delivery system. Complete occlusion
of PDA was observed after unscrewing the device,
although a small protrusion of the device into the
aorta was observed (with 8 mm gradient in ECHO
Doppler) (Fig. 5). Procedural time was 40 min, flu-
oroscopy time 5.2 min. ECHO examination, per-
formed after the procedure, revealed total occlusion
of PDA as well as the reduction of LVOT gradient
from 80 to 60 mm Hg.
Follow-up examinations of all patients were
scheduled: one, three, six and 12 months after the
procedure, and yearly thereafter. To date, no com-
plications at the six month follow-up have been
observed in the described group.
Discussion
Amplatzer occluders have been used world-
wide since the late 1990s and our experience con-
firmed the good clinical results obtained with these
devices for closure of 823 ASD, 100 PFO and 131
PDA. The important limitation in their application
is their high cost. Recently, new devices called
Occlutech Figulla and Cardio-O-Fix occluders, both
similar to Amplatzer, have been introduced to clini-
Figure 5. Small protrusion of 6/4 Cardio-O-Fix occluder
patent ductus arteriosus disc to aorta in six month old
infant after percutaneous closure of the duct.
cal practice. Comparative study of the Figulla ASD
occluder versus the Amplatzer Septal Occluder
(ASO) have shown that both devices are clinically
safe and effective in ASD closure. The Figulla oc-
cluder, however, has some disadvantages, such
as difficulties in selecting the correct size in larg-
er defects (fewer available sizes) and larger
sheath requirements [1]. Considering the great-
er variety of size of Cardio-O-Fix occluders, there
should be no problem using this device. Howev-
er, similarly to the observations of Pac et al. [1]
related to the Figulla occluder, we have found that
COF devices also required a larger sheath com-
pared to the ASO. This may also limit its applica-
tion in smaller children. The great advantage of
applying both the above mentioned devices is
their ability to close larger ASDs (in contrast to
other new devices, such as Helex or Cardia, which
are suitable only for smaller ASDs and have more
frequent complication rates) [4]. Moreover, our
experience shows that there need be no learning
curve using COF devices, because the implanta-
tion technique is similar to that for Amplatzer
devices. We decided to use these devices after
receiving many positive opinions on the subject
from internationally recognized leaders in inter-
ventional cardiology, who have used these devi-
ces in practice. Our decision was also strongly in-
fluenced by data from Chinese investigations (un-
fortunately not published yet) according to which,
more than 10,000 COF have been implanted with
good results. One important advantage of these
devices is their relatively low cost.
Two of the patients presented in this paper
with PDA had some peculiarities. The first adult
patient had recanalized PDA after a previous histo-
ry of its surgical ligation. This case confirmed our
experience that percutaneous closure of such PDAs
is feasible, although sometimes more laborious [4].
Zhang et al. [3] stated that in cases of abnormal PDA
morphology (as usually is seen in residual post-sur-
gical PDAs), the retrograde wire-guided technique
(applied by us in this patient as an arterio-venous
loop) offers an alternative approach to cannulate
a PDA that cannot be achieved by the traditional
antegrade wire-guided method.
The second case was an infant with PDA and
additionally hypertrophied cardiomyopathy causing
obstruction in LVOT (80 mm Hg in ECHO Doppler
study). We decided to close his PDA, expecting re-
duction of his left cavities overload. Our expecta-
tions were confirmed in practice (LVOT gradient
diminished from 80 to 60 mm). Although the final
result of PDA closure was positive, this case un-
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fortunately indicated that probably PDA COF de-
vices are not optimal for PDA closure in small chil-
dren. It is worth pointing out that the trans-septal
sheath was too soft, which explains its kinking. On
the other hand, Al Ata et al. [6] found a much high-
er rate of problems and complications in patients
with PDA with weight below 10 kg, in whom Am-
platzer Duct Occluder was used (our infant’s weight
was 8.9 kg). Probably, the new generation of Am-
paltzer Duct Occluder type II (with two retentional
discs connected by a waist is a better solution for
such patients [7].
Conclusions
Our preliminary experience with the applica-
tion of Cardio-O-Fix occluders for the closure of
atrial septal defect, foramen ovale and patent duc-
tus arteriosus, indicate that they are good and safe
devices, at least as shown in short term follow-up.
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